Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS.
暂无分享,去创建一个
L. Wood | K. Kinzler | C. Bettegowda | B. Vogelstein | V. Velculescu | R. Leary | R. Hruban | N. Papadopoulos | T. Chan | A. Ho | J. Bishop | W. Westra | J. Fagin | H. Dralle | B. Nelkin | D. Ball | M. Sausen | R. Ghossein | N. Agrawal | R. Tufano | B. Robinson | Sheetal Bhan | Zubair Khan | Y. Jiao | R. Toledo | Nicholas J. Roberts | S. Toledo | L. Morris | T. Chan | Sérgio P. A. Toledo
[1] S. Broutin,et al. Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon. , 2012, The Journal of clinical endocrinology and metabolism.
[2] G. Cote,et al. Medullary thyroid carcinoma: who's on first? , 2012, Thyroid : official journal of the American Thyroid Association.
[3] K. Kinzler,et al. Low‐grade serous carcinomas of the ovary contain very few point mutations , 2012, The Journal of pathology.
[4] E. Baudin,et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] E. Giné,et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia , 2011, Nature Genetics.
[6] A. Jemal,et al. Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.
[7] H. Schulten,et al. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma. , 2011, Anticancer research.
[8] A. Sivachenko,et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. , 2011, The New England journal of medicine.
[9] S. Sebti,et al. Targeting protein prenylation for cancer therapy , 2011, Nature Reviews Cancer.
[10] S. Sugano,et al. Frequent pathway mutations of splicing machinery in myelodysplasia , 2011, Nature.
[11] Yuchen Jiao,et al. Mutations in CIC and FUBP1 Contribute to Human Oligodendroglioma , 2011, Science.
[12] Michael A Choti,et al. Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma , 2011, Nature Genetics.
[13] R. Gibbs,et al. Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1 , 2011, Science.
[14] V. Leite,et al. High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas. , 2011, The Journal of clinical endocrinology and metabolism.
[15] Tian-Li Wang,et al. Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma , 2010, Science.
[16] M. Goldberg,et al. The cellular response to DNA damage: a focus on MDC1 and its interacting proteins. , 2010, Nucleus.
[17] M. Santoro,et al. Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets. , 2009, Journal of molecular endocrinology.
[18] R. Seethala. Prognostic Significance of Somatic RET Oncogene Mutations in Sporadic Medullary Thyroid Cancer: A 10-Year Follow-Up Study , 2009 .
[19] P. Engstrom. Systemic Therapy for Advanced or Metastatic Colorectal Cancer: National Comprehensive Cancer Network Guidelines for Combining Anti‐Vascular Endothelial Growth Factor and Anti‐Epidermal Growth Factor Receptor Monoclonal Antibodies with Chemotherapy , 2008, Pharmacotherapy.
[20] G. Parmigiani,et al. Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.
[21] D. Busam,et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.
[22] A. Pinchera,et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. , 2008, The Journal of clinical endocrinology and metabolism.
[23] Y. Kloog,et al. Inhibitors of chronically active ras: potential for treatment of human malignancies. , 2008, Recent patents on anti-cancer drug discovery.
[24] E. Baudin,et al. New therapeutic approaches to treat medullary thyroid carcinoma , 2008, Nature Clinical Practice Endocrinology &Metabolism.
[25] A. Sparks,et al. The Genomic Landscapes of Human Breast and Colorectal Cancers , 2007, Science.
[26] D. Ball. Medullary thyroid cancer: monitoring and therapy. , 2007, Endocrinology and metabolism clinics of North America.
[27] S. Roman,et al. Prognosis of medullary thyroid carcinoma , 2006, Cancer.
[28] G. Parmigiani,et al. The Consensus Coding Sequences of Human Breast and Colorectal Cancers , 2006, Science.
[29] G. Viglietto,et al. The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins. , 2006, Cancer research.
[30] R. Weichselbaum,et al. gamma-H2AX as a therapeutic target for improving the efficacy of radiation therapy. , 2006, Current cancer drug targets.
[31] P. Ladenson,et al. Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. , 2005, The Journal of clinical endocrinology and metabolism.
[32] M. Xing,et al. BRAF mutation in thyroid cancer. , 2005, Endocrine-related cancer.
[33] H. Varmus,et al. KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib , 2005, PLoS medicine.
[34] D. Tuveson,et al. Ductal pancreatic cancer in humans and mice. , 2005, Cold Spring Harbor symposia on quantitative biology.
[35] E. Petricoin,et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. , 2003, Cancer cell.
[36] Scott E Kern,et al. Focus on pancreas cancer. , 2002, Cancer cell.
[37] M. Takahashi,et al. The GDNF/RET signaling pathway and human diseases. , 2001, Cytokine & growth factor reviews.
[38] K. Herfarth,et al. Absence of TP53 alterations in pheochromocytomas and medullary thyroid carcinomas , 1997, Genes, chromosomes & cancer.
[39] B. Nelkin. Progression of Medullary Thyroid Carcinoma , 1996 .
[40] H. Kurahashi,et al. Inactivation of the p53 Gene Is not Required for Tumorigenesis of Medullary Thyroid Carcinoma or Pheochromocytoma , 1992, Japanese journal of cancer research : Gann.
[41] G. Fleuren,et al. KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. , 1988, Nucleic acids research.